Chargement en cours...
CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malignancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is transfer of natural or engineered tumor-specific T-cells into patients, a so called “...
Enregistré dans:
| Publié dans: | Cancer Cell Int |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7493839/ https://ncbi.nlm.nih.gov/pubmed/32973401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-020-01546-8 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|